|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang
X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang P, Wang Y, Peng X, You G, Zhang W,
Yan W, Bao Z, Wang Y, Qiu X and Jiang T: Management and survival
rates in patients with glioma in China (2004–2010): A retrospective
study from a singleinstitution. J Neurooncol. 113:259–266. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bloch O, Crane CA, Fuks Y, Kaur R, Aghi
MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, et
al: Heat-shock protein peptide complex-96 vaccination for recurrent
glioblastoma: A phase II, single-arm trial. Neuro Oncol.
16:274–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitchell DA, Batich KA, Gunn MD, Huang MN,
Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE,
Desjardins A, et al: Tetanus toxoid and CCL3 improve dendritic cell
vaccines in mice and glioblastoma patients. Nature. 519:366–369.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phuphanich S, Wheeler CJ, Rudnick JD,
Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et
al: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine
for patients with newly diagnosed glioblastoma. Cancer Immunol
Immunother. 62:125–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schuster J, Lai RK, Recht LD, Reardon DA,
Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan
A, et al: A phase II, multicenter trial of rindopepimut (CDX-110)
in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol.
17:854–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC,
Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann
JE, Helseth E, et al: Therapeutic vaccination against autologous
cancer stem cells with mRNA-transfected dendritic cells in patients
with glioblastoma. Cancer Immunol Immunother. 62:1499–1509. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reardon DA, Wucherpfennig KW, Freeman G,
Wu CJ, Chiocca EA, Wen PY, Curry WT Jr, Mitchell DA, Fecci PE,
Sampson JH and Dranoff G: An update on vaccine therapy and other
immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines.
12:597–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weller M, Roth P, Preusser M, Wick W,
Reardon DA, Platten M and Sampson JH: Vaccine-based
immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol.
13:363–374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Srinivasan VM, Ferguson SD, Lee S,
Weathers SP, Kerrigan BCP and Heimberger AB: Tumor vaccines for
malignant gliomas. Neurotherapeutics. 14:345–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heimberger AB, Suki D, Yang D, Shi W and
Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma
patients. J Transl Med. 3:382005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chandramohan V, Mitchell DA, Johnson LA,
Sampson JH and Bigner DD: Antibody, T-cell and dendritic cell
immunotherapy for malignant brain tumors. Future Oncol. 9:977–990.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schuessler A, Smith C, Beagley L, Boyle
GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, et
al: Autologous T-cell therapy for cytomegalovirus as a
consolidative treatment for recurrent glioblastoma. Cancer Res.
74:3466–3476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bonifant CL, Jackson HJ, Brentjens RJ and
Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther
Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janakiram M, Chinai JM, Zhao A, Sparano JA
and Zang X: HHLA2 and TMIGD2: New immunotherapeutic targets of the
B7 and CD28 families. Oncoimmunology. 4:e10265342015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni L and Dong C: New B7 family checkpoint
in human cancers. Mol Cancer Ther. 16:1203–1211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zou W, Wolchok JD and Chen L: PD-L1
(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,
response biomarkers, and combinations. Sci Transl Med.
8:328rv42016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohaegbulam KC, Assal A, Lazar-Molnar E,
Yao Y and Zang X: Human cancer immunotherapy with antibodies to the
PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K,
Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling
inhibition for cancer immunotherapy: Mechanism, combinations, and
clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of antiPD-L1 antibody in patients with advanced
cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Wang Z, Wang Y1 Fan X, Zhang C, Ma
W, Qiu X and Jiang T: PD-1 related transcriptome profile and
clinical outcome in diffuse gliomas. Oncoimmunology.
7:e13827922017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janakiram M, Chinai JM, Fineberg S, Fiser
A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao
R, et al: Expression, clinical significance, and receptor
identification of the newest B7 family member HHLA2 protein. Clin
Cancer Res. 21:2359–2366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao R, Chinai JM, Buhl S, Scandiuzzi L,
Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD and Zang
X: HHLA2 is a member of the B7 family and inhibits human CD4 and
CD8 T-cell function. Proc Natl Acad Sci USA. 110:9879–9884. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Y, Yao S, Iliopoulou BP, Han X,
Augustine MM, Xu H, Phennicie RT, Flies SJ, Broadwater M, Ruff W,
et al: Chen. B7-H5 costimulates human T cells via CD28H. Nat
Commun. 4:20432013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eckel-Passow JE, Lachance DH, Molinaro AM,
Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML,
Smirnov IV, et al: Glioma groups based on 1p/19q, IDH, and TERT
promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Y and Cao X: The origin and function
of tumor-associated macrophages. Cell Mol Immunol. 12:1–4. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Groot AE and Pienta KJ: Epigenetic
control of macrophage polarization: Implications for targeting
tumor-associated macrophages. Oncotarget. 9:20908–20927. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arokiaraj MC: A novel targeted
angiogenesis technique using VEGF conjugated magnetic nanoparticles
and in-vitro endothelial barrier crossing. BMC Cardiovasc Disord.
17:2092017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pitulescu ME, Schmidt I, Giaimo BD,
Antoine T, Berkenfeld F, Ferrante F, Park H, Ehling M, Biljes D,
Rocha SF, et al: Dll4 and Notch signalling couples sprouting
angiogenesis and artery formation. Nat Cell Biol. 19:915–927. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yan H, Qiu W, Koehne de Gonzalez AK, Wei
JS, Tu M, Xi CH, Yang YR, Peng YP, Tsai WY, Remotti HE, et al:
HHLA2 is a novel immune checkpoint protein in pancreatic ductal
adenocarcinoma and predicts post-surgical survival. Cancer Lett.
442:333–340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhat KPL, Balasubramaniyan V, Vaillant B,
Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L,
James JD, Goodman LD, et al: Mesenchymal differentiation mediated
by NF-κB promotes radiation resistance in glioblastoma. Cancer
Cell. 24:331–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin N, Yan W, Gao K, Wang Y, Zhang J and
You Y: Prevalence and clinicopathologic characteristics of the
molecular subtypes in malignant glioma: A multi-institutional
analysis of 941 cases. PLoS One. 9:e948712014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kumar V, Donthireddy L, Marvel D,
Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P,
Behera R, Goins MA, et al: Cancer-associated fibroblasts neutralize
the anti-tumor effect of CSF1 receptor blockade by inducing
PMN-MDSC infiltration of tumors. Cancer Cell. 32:654–668.e5. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kamran N, Alghamri MS, Nunez FJ, Shah D,
Asad AS, Candolfi M, Altshuler D, Lowenstein PR and Castro MG:
Current state and future prospects of immunotherapy for glioma.
Immunotherapy. 10:317–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liang YX, Lu JM, Mo RJ, He HC, Xie J,
Jiang FN, Lin ZY, Chen YR, Wu YD, Luo HW, et al: E2F1 promotes
tumor cell invasion and migration through regulating CD147 in
prostate cancer. Int J Oncol. 48:1650–1658. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gartel AL: FOXM1 in cancer: Interactions
and vulnerabilities. Cancer Res. 77:3135–3139. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rundle S, Bradbury A, Drew Y and Curtin
NJ: Targeting the ATR-CHK1 axis in cancer therapy. Cancers (Basel).
9(pii): E412017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koirala P, Roth ME, Gill J, Chinai JM,
Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M,
et al: HHLA2, a member of the B7 family, is expressed in human
osteosarcoma and is associated with metastases and worse survival.
Sci Rep. 6:311542016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu Z and Dong W: Overexpression of HHLA2,
a member of the B7 family, is associated with worse survival in
human colorectal carcinoma. Onco Targets Ther. 11:1563–1570. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shimonosono M, Arigami T, Yanagita S,
Matsushita D, Uchikado Y, Kijima Y, Kurahara H, Kita Y, Mori S,
Sasaki K, et al: The association of human endogenous retrovirus-H
long terminal repeat-associating protein 2 (HHLA2) expression with
gastric cancer prognosis. Oncotarget. 9:22069–22078. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Janakiram M, Shah UA, Liu W, Zhao A,
Schoenberg MP and Zang X: The third group of the B7-CD28 immune
checkpoint family: HHLA2, TMIGD2, B7×, and B7-H3. Immunol Rev.
276:26–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xiao Y and Freeman GJ: A New B7:CD28
family checkpoint target for cancer immunotherapy: HHLA2. Clin
Cancer Res. 21:2201–2203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Z, Wang Z, Zhang C, Liu X, Li G, Liu
S, Sun L, Liang J, Hu H, Liu Y, et al: Genetic and clinical
characterization of B7-H3 (CD276) expression and epigenetic
regulation in diffuse brain glioma. Cancer Sci. 109:2697–2705.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou Z, Luther N, Ibrahim GM, Hawkins C,
Vibhakar R, Handler MH and Souweidane MM: B7-H3, a potential
therapeutic target, is expressed in diffuse intrinsic pontine
glioma. J Neurooncol. 111:257–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Loos M, Hedderich DM, Ottenhausen M, Giese
NA, Laschinger M, Esposito I, Kleeff J and Friess H: Expression of
the costimulatory molecule B7-H3 is associated with prolonged
survival in human pancreatic cancer. BMC Cancer. 9:4632009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu
KF, Zhao JM, Zhang GB and Zhang XG: Relationship between
co-stimulatory molecule B7-H3 expression and gastric carcinoma
histology and prognosis. World J Gastroenterol. 12:457–459. 2006.
View Article : Google Scholar : PubMed/NCBI
|
